Source: www.benzinga.com/press-releases
Author: press release

Oncolytics Biotech Inc. (“Oncolytics”) today announced that it has been granted its 33rd U.S. Patent, # 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

“This patent supports our expanding clinical program, including our first Phase III study, looking at Reolysin(R) in combination with a range of chemotherapeutic agents,” said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. “Many of our studies enroll patients that did not previously respond to chemotherapy, including our Phase III study in patients with platinum refractory head and neck cancers.”

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using Reolysin(R), its proprietary formulation of the human reovirus.